- Home
- FLC vs ACHV Comparison
FLC vs ACHV Comparison
Compare FLC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | ACHV |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.9M | 726.5M |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FLC | ACHV |
|---|---|---|
| Price | $15.64 | $7.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $13.83 |
| AVG Volume (30 Days) | 35.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.54 | $2.62 |
| 52 Week High | $18.09 | $8.64 |
Technical Indicators
Market Signals| Indicator | FLC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 27.43 | 53.53 |
| Support Level | N/A | $7.01 |
| Resistance Level | $17.00 | $8.56 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 17.65 | 62.91 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.